J 2024

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire

HALIMI, Jean-Michel, Pantelis SARAFIDIS, Michel AZIZI, Grzegorz BILO, Thilo BURKARD et. al.

Basic information

Original name

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire

Authors

HALIMI, Jean-Michel, Pantelis SARAFIDIS, Michel AZIZI, Grzegorz BILO, Thilo BURKARD, Michael BURSZTYN, Miguel CAMAFORT, Neil CHAPMAN, Santina COTTONE, de Backer TINE, Jaap DEINUM, Philippe DELMOTTE, Maria DOROBANTU, Michalis DOUMAS, Rainer DUSING, Beatrice DULY-BOUHANICK, Jean-Pierre FAUVEL, Pierre FESLER, Zbigniew GACIONG, Eugenia GKALIAGKOUSI, Daniel GORDIN, Guido GRASSI, Charalampos GRASSOS, Dominique GUERROT, Justine HUART, Raffaele IZZO, Fernando Jaen AGUILA, Zoltan JARAI, Thomas KAHAN, Ilkka KANTOLA, Eva KOCIANOVA, Florian P LIMBOURG, Marilucy LOPEZ-SUBLET, Francesca MALLAMACI, Athanasios MANOLIS, Maria MARKETOU, Gert MAYER, Alberto MAZZA, Iain M MACINTYRE, Jean-Jacques MOURAD, Maria Lorenza MUIESAN, Edgar NASR, Peter NILSSON, Anna OLIVERAS, Olivier ORMEZZANO, Vitor PAIXAO-DIAS, Ioannis PAPADAKIS, Dimitris PAPADOPOULOS, Sabine PERL, Jorge POLONIA, Roberto PONTREMOLI, Giacomo PUCCI, Nicolas Roberto ROBLES, Sebastien RUBIN, Luis Miguel RUILOPE, Lars Christian RUMP, Sahrai SAEED, Elias SANIDAS, Riccardo SARZANI, Roland SCHMIEDER, Francois SILHOL, Sekib SOKOLOVIC, Marit SOLBU, Miroslav SOUČEK (203 Czech Republic, belonging to the institution), George STERGIOU, Isabella SUDANO, Ramzi TABBALAT, Istemihan TENGIZ, Helen TRIANTAFYLLIDI, Konstontinos TSIOUFIS, Jan VACLAVIK, van der Giet MARKUS, Van der Niepen PATRICIA, Franco VEGLIO, Reto M VENZIN, Margus VIIGIMAA, Thomas WEBER, Jiri WIDIMSKY, Gregoire WUERZNER, Parounak ZELVEIAN, Pantelis ZEBEKAKIS, Stephan LUEDERS, Alexandre PERSU, Reinhold KREUTZ and Liffert VOGT

Edition

Journal of Hypertension, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0263-6352

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.900 in 2022

Organization unit

Faculty of Medicine

UT WoS

001290622400001

Keywords in English

albuminuria; chronic kidney disease; glomerular filtration rate; hypertension; management; screening

Tags

Tags

International impact, Reviewed
Změněno: 6/9/2024 07:50, Mgr. Tereza Miškechová

Abstract

V originále

Objective: Real-life management of hypertensive patients with chronic kidney disease (CKD) is unclear. Methods: A survey was conducted in 2023 by the European Society of Hypertension (ESH) to assess management of CKD patients referred to ESH-Hypertension Excellence Centres (ESH-ECs) at first referral visit. The questionnaire contained 64 questions with which ESH-ECs representatives were asked to estimate preexisting CKD management quality. Results: Overall, 88 ESH-ECs from 27 countries participated (fully completed surveys: 66/88 [75.0%]). ESH-ECs reported that 28% (median, interquartile range: 1550%) had preexisting CKD, with 10% of them (5- 30%) previously referred to a nephrologist, while 30% (15-40%) had resistant hypertension. The reported rate of previous recent (<6 months) estimated glomerular filtration rate (eGFR) and urine albumin- creatinine ratio (UACR) testing were 80% (50- 95%) and 30% (15- 50%), respectively. The reported use of renin-angiotensin system blockers was 80% (70-90%). When a nephrologist was part of the ESH-EC teams the reported rates SGLT2 inhibitors (27.5% [20- 40%] vs. 15% [10-25], P = 0.003), GLP1-RA (10% [10- 20%] vs. 5% [5- 10%], P = 0.003) and mineralocorticoid receptor antagonists (20% [1030%] vs. 15% [10- 20%], P = 0.05) use were greater as compared to ESH-ECs without nephrologist participation. The rate of reported resistant hypertension, recent eGFR and UACR results and management of CKD patients prior to referral varied widely across countries. Conclusions: Our estimation indicates deficits regarding CKD screening, use of nephroprotective drugs and referral to nephrologists before referral to ESH-ECs but results varied widely across countries. This information can be used to build specific programs to improve care in hypertensives with CKD.